News

Latest updates from Engimata
Image and text of Mitra for MIT Sandbox Women EntrepreneursImage and text of Mitra for MIT Sandbox Women Entrepreneurs
Nov 12, 2020

Engimata Founder featured by MIT Sandbox

"Dr. Mitra Mosharraf MBA ’20 CEO of Engimata, Inc. is working to improve vaccine efficiency and enhance vaccine stability. Advice to women entrepreneurs: “Do not be afraid to fail. Failure is just a new starting point that helps us grow until we find the right path.”
Original Post
Engimata LogoEngimata Logo
Aug 28, 2020

A freeze-dried COVID-19 vaccine to improve the immunization supply chain

There is an urgent need for a COVID-19 vaccine. Currently, multiple COVID-19 vaccines are in various stages of development, with Moderna, Pfizer, Sanofi, Johnson & Johnson and AstraZenecca at the frontline. Both Moderna and Pfizer are developing mRNA vaccines that must be stored and transported at -70 °C or -20 °C. This greatly limits their distribution throughout the world because of the complicated and expensive supply chain needed to distribute these vaccines*.

Engimata has focused on development of vaccines that can be transported and stored outside the cold supply chain. We have recently developed a thermostable COVID-19 vaccine that, unlike other vaccines being developed, does not require a complicated cold-chain for transportation and distribution.
​​​​​​​
Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.